Literature DB >> 7614955

Antimicrobial chemotherapy of human infection due to Listeria monocytogenes.

E M Jones1, A P MacGowan.   

Abstract

Listeriosis is an uncommon infection, but when it occurs it carries a high mortality rate. Early diagnosis is essential and thereafter appropriate antimicrobial chemotherapy. Ampicillin or penicillin plus gentamicin remains the treatment of choice for most manifestations of listeriosis, and adequate doses must be given, i.e. greater than 6g/day of ampicillin or penicillin. Co-trimoxazole appears to be an excellent alternative agent with good penetration into the cerebrospinal fluid. Vancomycin is an appropriate agent for the treatment of primary bacteraemia but does not cross the blood-brain barrier sufficiently well to be useful in meningitis, while erythromycin may be used to treat listeriosis in cases of pregnancy. Treatment of bacteraemia requires one to two weeks' therapy, while meningitis cases may need to be treated for longer; for example, it has been found that most patients with acute meningitis in the UK were treated for 20 days. Infective endocarditis needs treatment for six to eight weeks. Doses should be varied with patients' altered organ function and antimicrobial serum monitoring performed when appropriate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614955     DOI: 10.1007/BF02310351

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  111 in total

1.  Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Penicillin-binding protein 3 of Listeria monocytogenes as the primary lethal target for beta-lactams.

Authors:  M F Vicente; J C Pérez-Dáz; F Baquero; M Angel de Pedro; J Berenguer
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Prosthetic hip infection caused by Listeria monocytogenes.

Authors:  E Arathoon; S B Goodman; K L Vosti
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

4.  Listeria meningitis--in vitro sensitivities to co-trimoxazole, penicillins and gentamicin.

Authors:  M G Prichard; H M Miles; E R Pavillard
Journal:  Aust N Z J Med       Date:  1983-02

5.  Influence of several antibiotics, singly and in combination, on the growth of Listeria monocytogenes.

Authors:  R C Gordon; F F Barrett; D J Clark
Journal:  J Pediatr       Date:  1972-04       Impact factor: 4.406

6.  Ampicillin-resistant Listeria monocytogenes meningitis in a previously healthy 14-year-old athlete.

Authors:  M F Rapp; H A Pershadsingh; J W Long; J M Pickens
Journal:  Arch Neurol       Date:  1984-12

7.  Listeria monocytogenes endophthalmitis with a black hypopyon.

Authors:  R L Abbott; R K Forster; G Rebell
Journal:  Am J Ophthalmol       Date:  1978-11       Impact factor: 5.258

8.  Liposome-encapsulated ampicillin against Listeria monocytogenes in vivo and in vitro.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink
Journal:  Infection       Date:  1988       Impact factor: 3.553

9.  Bacterial endocarditis due to Listeria monocytogenes in a pregnant diabetic.

Authors:  C A Holshouser; R Ansbacher; T McNitt; R Steele
Journal:  Obstet Gynecol       Date:  1978-01       Impact factor: 7.661

10.  Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults.

Authors:  C E Cherubin; J S Marr; M F Sierra; S Becker
Journal:  Am J Med       Date:  1981-08       Impact factor: 4.965

View more
  16 in total

Review 1.  Antibiotic resistance in Listeria spp.

Authors:  E Charpentier; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Acute obstructive hydrocephalus complicating bacterial meningitis. In meningitis, one antibiotic is better than than two.

Authors:  C Settle; M H Wilcox
Journal:  BMJ       Date:  1999-01-09

3.  Occupational asthma in an isothiazolinone manufacturing plant.

Authors:  S J Bourke; R P Convery; S C Stenton; R M Malcolm; D J Hendrick
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 4.  Management of listeriosis.

Authors:  H Hof; T Nichterlein; M Kretschmar
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  Selective pharmacologic inhibition of a PASTA kinase increases Listeria monocytogenes susceptibility to β-lactam antibiotics.

Authors:  Daniel A Pensinger; Matthew T Aliota; Adam J Schaenzer; Kyle M Boldon; Israr-ul H Ansari; William J B Vincent; Benjamin Knight; Michelle L Reniere; Rob Striker; John-Demian Sauer
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

6.  Emergence of the trimethoprim resistance gene dfrD in Listeria monocytogenes BM4293.

Authors:  E Charpentier; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Coselection of cadmium and benzalkonium chloride resistance in conjugative transfers from nonpathogenic Listeria spp. to other Listeriae.

Authors:  S Katharios-Lanwermeyer; M Rakic-Martinez; D Elhanafi; S Ratani; J M Tiedje; S Kathariou
Journal:  Appl Environ Microbiol       Date:  2012-08-17       Impact factor: 4.792

Review 8.  Update on Listeria monocytogenes infection.

Authors:  Nancy F Crum
Journal:  Curr Gastroenterol Rep       Date:  2002-08

9.  Efflux pump Lde is associated with fluoroquinolone resistance in Listeria monocytogenes.

Authors:  Sylvain Godreuil; Marc Galimand; Guy Gerbaud; Christine Jacquet; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997).

Authors:  Amar Safdar; Donald Armstrong
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.